NCT03319667: Phase 3 - Isatuximab, Bortezomib, Lenalidomide and Dexamethasone NDMM (IMROZ)
NCT03091257: Phase 1 - Dabrafenib and/or Trametinib in Patients With Relapsed Refractory Myeloma
NCT03106324: Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma -TNE
NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab MGUS / Smoldering Myeloma SMM
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
FDA Approved for RRMM: Daratumumab + Pomalidomide & Dexamethasone
Myeloma Canada: Multiple Myeloma Patient Handbook
Phase II HOVON 143 Study: Ixazomib, Dara and Low Dose Dex in Intermediate-Fit Patients NDMM
NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Myeloma NDMM
NCT03104842: Phase 2 - GMMG - CONCEPT - Eval. iNduction, Consol. & Maint. Isatuximab Carf Len. & Dex
Cleveland Clinic: How to Give Subcutaneous Chemotherapy Injections
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in RRMM Multiple Myeloma
NCT03338972: Phase 1 - Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 in RRMM
NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Myeloma
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1
NCT03218683: Phase 1/2: Study of AZD5991 Alone or with Venetoclax in Relapsed Hem Malignancies
NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)
NCT03119363: Treating Cancer-Related Fatigue Through Systematic Light Exposure
Penn Medicine, the Abramson Cancer Center: CAR-T Cell Therapy: Using Healthy Cells to Fight Cancer
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
SITC - Society for Immunotherapy of Cancer IMMUNOTHERAPY: The Path to a Cancer Cure
Roswell Park - REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients
NCT03078452: Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy - Multiple Myeloma